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A 38-year-old female patient with neither diagnosis 
nor family history of any heart disease was admitted to 
the regional hospital with sustained ventricular tachycar-
dia (220 bpm). Tachyarrhythmia was successfully treated 
with intravenous amiodarone. Total time of sustained 
ventricular tachycardia was no more than 1 h (from the 
start of symptoms at home to the end of arrhythmia in 
the emergency department in a  regional hospital). The 
pulmonary congestion was revealed both in physical and 
X-ray examination. Extremely high levels of high-sen-
sitivity troponin I  (> 40 000 ng/l) as well as NT-proBNP 
(21 055 pg/ml) were detected. In control sampling after 
several days the level of troponin I  was still very high: 
39 185 ng/l. The patient was transferred to our tertia-
ry center where in the face of a prolonged period of an 
extremely high level of troponin I, the decision to per-
form coronary angiography was made. The coronary ar-
tery angiogram was normal. Echocardiography revealed 
myocardial hypertrophy and mild dilatation of the left 
ventricle (LV). The LV ejection fraction (EF) was low, i.e. 
28%. The suspicion of the starting phase of the dilative 
stage (burn-out) of hypertrophic cardiomyopathy (HCM) 
was suggested and cardiac magnetic resonance (CMR) 
imaging with gadolinium contrast was proposed to ex-
plore the hypothesis.
The CMR confirmed myocardial hypertrophy dis-
tributed in several segments. Maximal thickness of the 
myocardium was 19 mm in diastole. Total LV mass was 
increased to 303 g (156 g/m2).
Mild LV cavity dilatation was characterized by the 
following parameters: end diastolic volume of 318 ml 
(163 ml/m2) and end systolic volume of 271 ml (112 ml/
m2). Low EF was confirmed at the level of 30%. A large 
amount (29.6%) of late gadolinium enhancement (LGE) 
with a diffused pattern was noted (Figure 1).
An episode of sustained ventricular tachycardia has 
been recognized as a major risk factor of sudden cardiac 
death (SCD). Therefore, an implantable cardioverter-de-
fibrillator with resynchronization (R-ICD) was implanted. 
This decision was supported by a  wide QRS (130 ms) 
complex and NYHA class defined as III during hospitaliza-
tion. Resynchronization was introduced due to low LV EF. 
The decision of electrotherapy as secondary prevention 
of SCD was supported by a massive amount of LGE rep-
resenting the arrhythmia substrate. Unfortunately, R-ICD 
implantation will not allow follow-up examinations with 
CMR to be made in the future.
In our case the large amount of LGE was associated 
with lower EF. Thus, the heart was probably in an initial 
phase of evolution to the dilated end-stage (burning out) 
phase which occurs in 5–10% of patients with HCM [1].
One of the strongest and most consistent observa-
tions derived from a number of contemporary cross-sec-
tional studies is the inverse relationship between EF and 
LGE in HCM. The LGE extent is greatest in HCM patients 
with LV EF < 50% (heralding the development of the 
burn-out phase) [1].
In a recent study on patients undergoing transplan-
tation (excised heart) due to end-stage HCM, more than 
one-third of the LV myocardium of those patients was 
replaced by fibrosis [2]. In our patient a similar value of 
LGE (near 30%) was detected.
In a very recent meta-analysis, quantitative LGE by CMR 
exhibited a substantial and independent of baseline char-
acteristics value in the prediction of SCD. Thus, assessment 
of LGE can be used as an effective tool for risk stratification 
of patients with HCM [3]. An LGE value > 15% has been 
recognized as a strong risk factor for ventricular fibrillation.
An increased (even persistently) level of troponin in 
HCM has been described in recently published papers. 
Rafał Hładij et al. Troponin release in hypertrophic cardiomyopathy
179Advances in Interventional Cardiology 2017; 13, 2 (48)
The scale of the phenomenon is large [4] as a positive 
test for high-sensitivity troponin T was detectable in 3/4 
and elevated in 1/4 of patients with HCM. In obstructive 
HCM, troponin I  was also shown to be correlated with 
the extent of LV hypertrophy [5]. In addition, this bio-
marker was an independent predictor of the presence of 
myocardial fibrosis in CMR [6]. Recently, we reported an 
increased level of troponin after supraventricular tachy-
cardia 180 bpm in a  patient with apical HCM [7]. This 
observation as well as the present case suggests that 
tachycardia may be a trigger for troponin release in pa-
tients with HCM.
Importantly, from a therapeutic point of view, it has 
been documented in HCM [8] that increased troponin 
release may be present in such patients  and may be 
temporarily enhanced by exercise and decreased with 
β-blockers. Possibly in our patient sustained ventricular 
tachycardia may have mimicked very extensive exercise 
and may have been responsible for a huge release of tro-
ponin.
In conclusion, CMR imaging may be helpful as a di-
agnostic tool in patients with life-threatening sustained 
ventricular tachyarrhythmia (without a  history of any 
heart disease) and an ambiguous echocardiographic pic-
ture. Extremely high levels of troponin I despite a normal 
coronary artery angiogram may indicate development 
of the burn-out phase of the disease, called the dilative 
form of HCM.
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Figure 1. Massively diffused late enhancement 
visualized in short axis imaging
